Valeant Pharmaceuticals issued its delayed annual report on Friday, which will help it stave off a default on its $30 billion debt. » Read More
Bill Miller said the troubled pharmaceutical company should be worth about double its current trading price.
Bill Miller, LMM LLC Chairman & CIO, talks about his view that stock in the beleaguered company Valeant Pharmaceuticals is worth at least $60.
News of potential sanctions against blood-testing company Theranos was not surprising, business school professors told CNBC.
Chinese researchers have reported successfully adding HIV-resistant mutations into human embryos, according to an article in Nature on Friday.
Under-fire drug giant Valeant Pharmaceuticals International won't put Bausch & Lomb on the block, investor Bill Ackman told CNBC.
Is the biotech industry having a good year or a slow one? Expert analysts weigh in on CNBC's "Power Lunch."
Martine Rothblatt, United Therapeutics, weighs in on why the Treasury's tax inversion rule in good for big pharma. If the corporate tax rate was dropped in the U.S. then there would be no reason for inversions to go on, says Rothblatt.
The inversion clampdown makes it more difficult for companies to stay competitive, says Sanford Bernstein's Ronny Gal.
Pfizer is worth a lot more than it is trading at, based on the potential for future spin-offs, explains Bill Smead of Smead Capital Management.
Merck CEO Kenneth Frazier said a flawed corporate tax system drives inversion deals that have drawn the government's ire.
Merck CEO Kenneth Frazier talks with CNBC's Meg Tirrell about his company's avoidance of tax inversion deals, as well as his views on the M&A environment and drug pricing.
Bill Ackman says he expects Pershing Square to regain most of its investment in Valeant, reports CNBC's Mary Thompson. John Spallanzani, GFI Group, weighs in.
The Pfizer, Allergan merger effort has reignited a debate over corporate inversions, says Yevgeniy Feyman. But US jobs are not really at stake.
A failed $160 billion merger between Pfizer and Allergan left experts contemplating whether more deals could be hit by new tax rules.
Billionaire investor William Ackman faced close questioning on Wednesday when he detailed his hedge fund's biggest-ever quarterly loss.
CEO Brent Saunders spoke after Pfizer and Allergan terminated their $160B merger because of surprise changes in U.S. tax regulations.
Valeant Pharmaceuticals said a committee completed a review of its accounting practices and did not find anything that would require restatements.
Raghuram Selvaraju from Rodman & Renshaw explains that Pfizer could have second thoughts about acquiring Allergan if tax benefits are negated.
The "Fast Money" traders give their final trades of the day.
Les Funtleyder, E Squared Asset Management Portfolio Manager, and David Seaburg, Cowen & Company Managing Director and Head of Sales & Trading, discuss the biotech sector and how investors should approach it.
Get the best of CNBC in your inbox